Nebivolol is a lipophilic β 1-blocker. It is devoid of intrinsic sympathomimetic or membrane
stabilising activity but appears to have nitric oxide-mediated vasodilatory effects. Nebivolol is …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …

A double-blind, randomised, parallel-group trial was conducted in patients with essential
hypertension in British general practices, of nebivolol 5 mg, atenolol 50 mg, and placebo …

Nebivolol is a β-blocker under US Food and Drug Administration review for the treatment of
hypertension. The unique pharmacologic properties of nebivolol include high specificity for …

The efficacy and acceptability of 5 mg nebivolol once daily, a long-acting, vasodilating
cardioselective [beta] blocker that additionally facilitates the L-arginine/nitric oxide system …

The objective of this 12‐week double‐blind randomized multicentre study was to compare
the efficacy and tolerability of nebivolol, a recently developed beta‐blocking agent with …

Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …

Nebivolol has been adequately tested in clinical efficacy trials of patients with mild
hypertension. Clinical efficacy trials or their metaanalyses did not accurately predict the …

Nebivolol is a cardioselective lipophilic β-blocker devoid of intrinsic sympathomimetic and
membrane-stabilizing actions. The pharmacological profile differs from that of conventional …